Last reviewed 2026-05-13 · How we verify

ABP 654

ABP 654 is a monoclonal antibody that blocks RANKL (receptor activator of nuclear factor kappa-B ligand) to inhibit osteoclast formation and bone resorption.

ABP 654 is a monoclonal antibody that blocks RANKL (receptor activator of nuclear factor kappa-B ligand) to inhibit osteoclast formation and bone resorption. Used for Giant cell tumor of bone, Bone metastases in solid tumors.

At a glance

Mechanism of action

ABP 654 binds to RANKL, a key cytokine in the RANK/RANKL/OPG pathway that drives osteoclast differentiation and activation. By neutralizing RANKL, the drug reduces bone resorption and is being developed for conditions characterized by excessive bone loss or osteoclast-mediated pathology. This mechanism is similar to denosumab, an established RANKL inhibitor.

Approved indications

• Giant cell tumor of bone
• Bone metastases in solid tumors

Common side effects

• Hypocalcemia
• Osteonecrosis of the jaw
• Infection
• Fatigue

Key clinical trials

• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (PHASE3)
• A Study to Investigate Interchangeability of ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• ABP 654 CI brief — competitive landscape report
• ABP 654 updates RSS · CI watch RSS
• Amgen portfolio CI